Leadership

President and Chief Executive Officer

Sandrock has been President and Chief Executive Officer of Voyager, as well as a member of the board of directors, since 2022. He also currently serves as a member of the board of directors for Verge Genomics, Inc.; Transition Bio, Inc.; and Neurimmune, Inc. Sandrock joined Voyager following a prolific career in biopharmaceutical drug development, in which he spent 23 years at Biogen where he identified and developed novel therapies for a variety of serious diseases. While at Biogen, Sandrock served in positions of increasing responsibility, culminating in his service as Executive Vice President, Research and Development. He also served as Chief Medical Officer and held a seat on the Biogen Executive Committee. Over the course of his tenure, he led the discovery and development, and regulatory approval of numerous medicines including: ADUHELM™, PLEGRIDY®, SPINRAZA®, TECFIDERA®, and TYSABRI®. Sandrock earned a B.A. in human biology from Stanford University, an M.D. from Harvard Medical School, and a Ph.D. in neurobiology from Harvard University. He completed an internship in medicine, a residency and chief residency in neurology, and a clinical fellowship in neuromuscular disease and clinical neurophysiology at Massachusetts General Hospital.

Chief Scientific Officer

Carter has been Chief Scientific Officer at Voyager since 2022. Starting in 2016 and prior to his role as CSO, Carter held roles of increasing responsibility at Voyager, most recently serving as senior vice president of research. He led novel gene therapy development programs and supported the development of the TRACER™ platform, the identification of novel AAV capsids, and the execution of multiple successful industry partnerships. Before joining Voyager, Carter served as the Senior Science Advisor to the Office of the Director of the Broad Institute of the Massachusetts Institute of Technology and Harvard, where he was the lead scientific advisor and manager for several internal and external science programs, with a focus on moving innovative science concepts toward the clinic. Previously, he oversaw research at BrainCells, Inc., as Senior Director of Biology, including evaluation of novel targets for CNS disease and the preclinical to clinical transition of the company’s lead program. Carter received a B.A. in genetics from Texas A&M University, a Ph.D. in genetics from Columbia University, and completed his postdoctoral training at the Salk Institute for Biomedical Research.

Chief Legal Officer

Fahey Sandell joined Voyager in 2023 as Chief Legal Officer. She has over 25 years of legal experience spanning in-house roles at multiple biotechnology and pharmaceutical companies. Prior to joining Voyager, she served as CLO, Corporate Secretary, and Compliance Officer of Jounce Therapeutics, Inc., where she was responsible for all legal matters, including supporting key license agreements with Gilead and the company’s merger agreement with Concentra Biosciences, LLC. Prior to joining Jounce, Fahey Sandell served as Vice President, General Counsel, Corporate Secretary and Compliance Officer at Vericel Corporation. Fahey Sandell previously held legal positions of increasing seniority at Millennium: The Takeda Oncology Company and Genzyme Corporation, and she has worked at multiple top-tier law firms. Fahey Sandell holds a B.A. from Duke University and a J.D. from Boston University School of Law.

Chief Medical Officer

Ferguson has been Chief Medical Officer at Voyager since joining the company in 2024. Ferguson held positions of increasing responsibility at Biogen, most recently serving as Vice President, Head of Neuromuscular Development Unit. During his tenure, he built and developed teams focused on neuromuscular and movement disorders, overseeing strategy for these areas across Biogen R&D. Notably, he led the team that developed QALSODY® (tofersen), the first genetically targeted therapy for SOD1 amyotrophic lateral sclerosis (ALS); this therapeutic received the first accelerated approval based on reduction of neurofilament, a surrogate biomarker pioneered by Ferguson, his team, and the broader ALS community. Overall, his teams at Biogen were responsible for nine successfully executed INDs and three proof-of-concept clinical trials and filings. Prior to joining Biogen, Ferguson was Assistant Professor of Neurology, Shriners Pediatric Research Center and Temple University School of Medicine. He received his M.D. and Ph.D. from University of Florida College of Medicine and his B.S. from University of Florida, Gainesville. He also completed a residency in neurology and a neuromuscular fellowship at the University of Pennsylvania.

Chief Financial Officer

Jorgensen has been Chief Financial Officer at Voyager since joining the company in July 2024. Previously, he was CFO at Vor Biopharma, overseeing finance, communications, facilities, GMP, and IT and raising over $400 million in public and private financings. Prior to this, Jorgensen managed global public and private healthcare investing for the Qatar Investment Authority, the State of Qatar’s sovereign wealth fund. Previously, he led pharma and biotech investing efforts on the all-cap equity healthcare team at Calamos Investments LLC. Jorgensen also covered mid- and large-cap biotech companies as an equity research analyst at Stifel, Nicolaus & Company, Incorporated. Before entering the financial sector, Jorgensen investigated the pathobiology of Parkinson’s disease as a postdoctoral scientist at Columbia University Irving Medical Center. He received his MBA from the Cornell SC Johnson College of Business, his Ph.D. in neuroscience from the University of Minnesota, and his B.A. from St. John’s University.

Morrison joined Voyager in 2022 with over 20 years of experience in healthcare public affairs, including strategic communications, investor relations and patient advocacy. She also serves on the board of directors for the Network of Tyrosinemia Advocates and on the advisory board for The Termeer Foundation. Prior to joining Voyager, Morrison served as Chief Corporate Affairs Officer for Saniona, where she built and led communications, investor relations, patient advocacy and government relations, in addition to serving as a member of the executive committee. She previously founded the consulting firm PR with Purpose, and her prior roles include Vice President of Communications and Patient Advocacy for rare disease company Sobi in North America, Head of Communications for Ironwood Pharmaceuticals, and reporter and editor for BioWorld Today, as well as various positions at multiple communications agencies. Morrison received a B.S. in marketing and biology from Tulane University.

Smith joined Voyager in 2020 as Chief Human Resources Officer. Before joining Voyager, she served as part of the Human Resources Leadership Team at Flagship Pioneering. Prior to Flagship, Smith was Global Human Resources Business Leader for Takeda Pharmaceuticals. She also served in global HR roles at Sanofi as well as Genzyme, Goldman Sachs and Young and Rubicam Advertising. Smith received a B.A. in history from Chestnut Hill College in Philadelphia and serves on the Board of Directors for Horse Hugs for Heroes, a therapeutic animal non-profit organization based in Maryland.

Swartz has served as Voyager’s Chief Operating Officer since 2022. She joined the company in 2021 as Senior Vice President, Portfolio Management and Patient Engagement. Prior to joining Voyager, she held several leadership positions at Genzyme Corporation and Sanofi Genzyme. She most recently served as Vice President, Patient and Product Services for Rare Diseases at Sanofi Genzyme and has held various additional positions including as Senior Vice President, Head of Global and U.S. Business Operations, and Chief of Staff to the Executive Vice President and Senior Director, Finance. Swartz served on the Sanofi Aventis Board of Directors and was a member of the Executive Community Relations Committee. Swartz received her B.A. in political science and government from Kenyon College.

Chair

Higgins has served on the board of directors since 2015 and as chairman of the board since 2019. He is currently also the chairman of the board of directors of Pulmatrix, Inc. and at Nocion Therapeutics, Inc. He also serves as a board member of Cyclerion Therapeutics, Inc.; Camp4 Therapeutics, Corp.; and Sea Pharmaceuticals, LLC. Higgins is a serial entrepreneur who has helped launch and build numerous companies during his career. He previously served as Entrepreneur-in-Residence at Polaris Partners. He also served as Senior Vice President, Chief Operating Officer of Ironwood Pharmaceuticals, Inc., and held a variety of senior business positions at Genzyme Corp., including Vice President of Corporate Finance and Vice President of Business Development. Higgins received a B.S. from Cornell University and an M.B.A. from the Amos Tuck School of Business at Dartmouth College.

Colón has been a member of Voyager’s board of directors since 2023. She serves as chair of the boards of directors of Bloom Science, Inc. and Emm Technology Ltd. She also serves as a member of the boards of directors of CareDx, Inc.; the Massachusetts Institute of Technology (MIT) Corporation (MIT’s Board of Trustees); the Biotechnology Innovation Organization (BIO); and Inaya Therapeutics, Inc. She is also a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). Colón brings over 25 years of experience in biopharma, genomics, healthcare and industrial biotechnology to the Voyager board. She has served as  President, CEO and Director of InCarda Therapeutics, Inc., and as President and CEO of ProterixBio. Previously, among multiple other roles, Colón served as a partner and senior advisor to New Science Ventures LLC., Senior Vice President and founding President of the Industrial Products Division at Precigen, Inc., (formerly Intrexon Corporation), and in various leadership roles at Gilead Sciences, Inc. and Affymetrix, Inc. (acquired by Thermo Fisher Scientific). Colón received her Ph.D. in chemical engineering from the Massachusetts Institute of Technology, where she was a National Science Foundation Fellow, and earned a B.S. in chemical engineering from the University of Pennsylvania, where she was a Benjamin Franklin Scholar.

Geraghty has served on Voyager’s board of directors since 2014. He also currently serves as chairman of the board of directors of Pieris Pharmaceuticals, Inc. and CanBridge Pharma, and as member of the board of directors of Fulcrum Therapeutics, Inc. and OMass Therapeutics Limited. He was previously an entrepreneur-in-residence at Third Rock Ventures and served earlier as Senior Vice President, North America Strategy and Business Development at Sanofi S.A. Geraghty held wide-ranging leadership positions at Genzyme, Corp., including Senior Vice President International Development and an executive officer, President of Genzyme Europe, General Manager cardiovascular, and Chairman, President and CEO of Genzyme Transgenics (now GTC Biotherapeutics, Inc.). Geraghty received a B.A. from Georgetown University, an M.S from the University of Pennsylvania, and a J.D. from Yale Law School.

Hyman has served on Voyager’s board of directors since 2015. He currently serves as chair of the board of directors of the Charles A. Dana Foundation (NY) and as a director of Cyclerion Therapeutics, Inc. and of the Stanley Center for Psychiatric Research at the Broad Institute of Harvard and MIT. Hyman is also a core faculty member of the Broad Institute and a Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology. Previously, Hyman served as provost of Harvard University, the university’s chief academic officer. Hyman has held various additional roles including director of the U.S. National Institute of Mental Health, various positions with the National Academy of Medicine, the Forum on Neuroscience and Nervous Systems Disorders, and the governing board of the National Research Council. He is a fellow of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science, former president of the Society for Neuroscience, former president of the American College of Neuropsychopharmacology, and a Distinguished Life Fellow of the American Psychiatric Association. Hyman received a B.A. from Yale College, an M.A. from the University of Cambridge, which he attended as a Mellon fellow, and an M.D. from Harvard Medical School.

Mackey has served on Voyager’s board of directors since 2022. She also serves as a member of the boards of directors of Avid Bioservices, Inc. and IDEAYA Biosciences, Inc. She is a seasoned life science executive with more than thirty years of operational experience, highlighted by her tenure as Senior Vice President, Global Research & Development, for Pfizer, Inc. During her tenure at Pfizer, Mackey led La Jolla Labs where she oversaw more than 1,000 staff, delivering a steady-state pipeline of more than two dozen development compounds. Prior to her role at Pfizer La Jolla, Mackey led Strategic Alliances at its R&D headquarters, where she gained extensive experience with both corporate and academic partnerships in the U.S. and global markets. Additionally, she led Pfizer’s U.S. R&D efforts in Genomic and Proteomic Sciences, which included biomarker and pharmacogenomics research. Mackey earned her B.S. and Ph.D. in microbiology from Cornell University.

Pierce has been a member of the board of directors since January 2017. He currently serves as entrepreneur-in-residence at Third Rock Ventures LLC. At Third Rock, he co-founded Ambys Medicines, Inc., and served as Chief Medical Officer. Pierce previously served in several roles at Biogen, Inc., including as Senior Vice President leading the hematology, cell and gene therapies division. Prior to Biogen, he served multiple roles in a variety of biopharmaceutical firms, including Bayer, AG; Inspiration Pharma, Ltd; Avigen, Inc.; Selective Genetics, Inc.; and Amgen, Inc., in the areas of tissue regeneration and hematology. Pierce is the co-author of more than 170 scientific papers and an inventor on more than 15 patents. He served on the medical and scientific advisory council, the board of directors and was President of the board of the National Hemophilia Foundation. Pierce also served on the Blood Products Advisory Committee at the FDA and the Committee on Blood Safety and Availability at the U.S. Department of Health and Human Services. He currently serves on the board of directors of the World Federation of Hemophilia and as the organization’s Vice President, Medical. Pierce received B.A. in biology, an M.D. and a Ph.D. in Immunology, all from Case Western Reserve University in Cleveland. He completed his postgraduate training in pathology and hematology research at Washington University in St. Louis.

Scangos has served on Voyager’s board of directors since 2023. He also currently serves as a member of the board of directors of Vir Biotechnology, Inc.; Agilent Technologies, Inc.; Octave Bioscience, Inc.; Rezo Therapeutics, Inc.; and the Bay Area chapter of Life Science Cares. Scangos previously served as the President and CEO for Vir, where he helped bring to market drugs for COVID-19 and Ebola. Prior to that, he spent several years as CEO and a member of the board of directors for Biogen, Inc., where he advanced a portfolio of medicines for neurological diseases including Alzheimer’s disease. Before joining Biogen, Scangos served more than a decade as President and CEO of oncology company Exelixis, Inc. Prior to joining industry, Scangos was a Professor of Biology at Johns Hopkins University. He received a B.A. in Biology from Cornell University and a Ph.D. in Microbiology from the University of Massachusetts.

Vitale has served on Voyager’s board of directors since 2020. She is the Chief People Officer at Omada Health, Inc. She is also a member of the board of directors for the Make-A-Wish Foundation and a co-founder of Partners for Wellbeing LLC, a boutique human resources consulting firm for which she previously served as Managing Partner. Previously, Vitale served as Senior Vice President and Chief Human Resource Officer at Genentech, Inc., a member of the Roche Group. Prior to Genentech, she held senior human resources roles at Procter & Gamble and CIGNA, Corp. Vitale received a B.B.A. from the University of Michigan and an M.B.A. from the Goizueta Business School at Emory University.